Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 3/20 | 0.40 |
| ▸ | JAK2 | O60674 | 2/20 | 0.40 |
| ▸ | JAK1 | P23458 | 2/20 | 0.40 |
| ▸ | TYK2 | P29597 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.38 |
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.38 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22180827 | 0.83 | HRH3 (0.43) | BRD4HDAC3HDAC1HDAC2 | |
| SCHEMBL23519498 | 0.83 | HDAC3 (0.33) | HDAC3HDAC1HDAC2 | |
| SCHEMBL15885816 | 0.71 | NOTUM (0.40) | CYP2C9CYP2C19LMNA | |
| SCHEMBL22084126 | 0.70 | GAA (0.37) | CYP2C9CYP2C19HDAC3HDAC1HDAC2 | |
| SCHEMBL15885998 | 0.69 | LMNA (0.41) | KDM4ELMNAMAPT | |
| SCHEMBL12747180 | 0.67 | EPHX2 (0.43) | KDM4E | |
| SCHEMBL15885921 | 0.67 | BRS3 (0.37) | JAK3JAK2BRD4 | |
| SCHEMBL31279028 | 0.66 | RAB9A (0.40) | BRD4CYP11B1CYP11B2MAPTGSK3B | |
| SCHEMBL28586308 | 0.66 | RAB9A (0.40) | BRD4CYP11B1CYP11B2MAPTGSK3B | |
| SCHEMBL3026559 | 0.66 | CYP2C9 (0.67) | CYP2C9CYP2C19HTR2BMAPK14MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11236047-B2 | Combination of isoindolinone derivatives with SGI-110 | ASTEX THERAPEUTICS LIMITED (GB) | 2022-02-01 | — | — | US | disclosed |
| US-20200207711-A1 | COMBINATION OF ISOINDOLINONE DERIVATIVES WITH SGI-110 | ASTEX THERAPEUTICS LIMITED (GB) | 2020-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11236047-B2 | Combination of isoindolinone derivatives with SGI-110 | SGK3, SGK2, GDI2 | JAK3 1655/4885JAK2 1626/4885JAK1 1644/4885 |
| US-20200207711-A1 | COMBINATION OF ISOINDOLINONE DERIVATIVES WITH SGI-110 | SGK3, SGK2, GDI2 | JAK3 1655/4885JAK2 1626/4885JAK1 1644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.